Moseley Investment Management Inc. Decreases Position in Pfizer Inc. (NYSE:PFE)

Share on StockTwits

Moseley Investment Management Inc. trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 4.1% in the fourth quarter, HoldingsChannel.com reports. The firm owned 21,713 shares of the biopharmaceutical company’s stock after selling 931 shares during the quarter. Moseley Investment Management Inc.’s holdings in Pfizer were worth $851,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in PFE. Nuveen Asset Management LLC grew its holdings in shares of Pfizer by 2,240.5% during the second quarter. Nuveen Asset Management LLC now owns 36,086,254 shares of the biopharmaceutical company’s stock worth $1,563,256,000 after purchasing an additional 34,544,423 shares during the last quarter. Natixis purchased a new stake in shares of Pfizer in the 2nd quarter valued at about $258,466,000. DNB Asset Management AS boosted its position in shares of Pfizer by 241.0% in the 3rd quarter. DNB Asset Management AS now owns 3,734,044 shares of the biopharmaceutical company’s stock valued at $134,164,000 after purchasing an additional 2,638,873 shares during the period. Eagle Asset Management Inc. boosted its position in shares of Pfizer by 84.9% in the 3rd quarter. Eagle Asset Management Inc. now owns 3,816,935 shares of the biopharmaceutical company’s stock valued at $137,142,000 after purchasing an additional 1,752,551 shares during the period. Finally, California Public Employees Retirement System boosted its position in shares of Pfizer by 5.3% in the 2nd quarter. California Public Employees Retirement System now owns 23,186,244 shares of the biopharmaceutical company’s stock valued at $1,004,428,000 after purchasing an additional 1,159,857 shares during the period. 70.21% of the stock is owned by hedge funds and other institutional investors.

PFE opened at $40.67 on Thursday. Pfizer Inc. has a 52 week low of $33.97 and a 52 week high of $44.56. The business has a 50 day moving average price of $38.90 and a two-hundred day moving average price of $38.18. The company has a quick ratio of 0.68, a current ratio of 0.90 and a debt-to-equity ratio of 0.55. The company has a market cap of $221.75 billion, a PE ratio of 13.56, a P/E/G ratio of 4.24 and a beta of 0.65.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.13. The company had revenue of $12.68 billion for the quarter, compared to the consensus estimate of $12.37 billion. Pfizer had a return on equity of 28.10% and a net margin of 30.57%. The company’s revenue was down 4.6% on a year-over-year basis. During the same period last year, the business posted $0.78 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.97 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 31st will be issued a dividend of $0.38 per share. The ex-dividend date is Thursday, January 30th. This is an increase from Pfizer’s previous quarterly dividend of $0.36. This represents a $1.52 annualized dividend and a dividend yield of 3.74%. Pfizer’s dividend payout ratio (DPR) is currently 48.00%.

Several research analysts have commented on PFE shares. ValuEngine raised Pfizer from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Zacks Investment Research raised Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price objective for the company in a report on Tuesday, October 1st. Credit Suisse Group restated a “hold” rating and set a $41.30 target price on shares of Pfizer in a research report on Wednesday, November 6th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Pfizer in a report on Tuesday, October 29th. Finally, Bank of America started coverage on shares of Pfizer in a research report on Wednesday, October 16th. They issued a “neutral” rating and a $37.00 price target for the company. Nine research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. Pfizer has a consensus rating of “Hold” and a consensus target price of $43.41.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: Bid-Ask Spread

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.